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and MTG patients. Additionally, hospitalizations in intensive care units (50% SG vs. 
22% MTG patients), emergency visits (21% SG vs. 6% MTG) and the presence of 
adenoma complications (73% SG vs. 44% MTG) constitute a source of cost increment 
in these patients. Patients who accomplish with the most strict study clinical control 
criteria (GH < 1.0 and IGF-1 < 100%) showed the lowest direct cost of illness (c6169 
vs. c12,990). CONCLUSIONS: The economic cost of acromegaly is dependent on the 
clinical control of the disease. Direct cost of illness is the half that the cost in non 
controlled patients.
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OBJECTIVES: To gain insight into the re-evaluation process of HTA agencies after 
an initial rejection and identify the adaptations that led to the approval of re-submitted 
dossiers. METHODS: Phase I: manual search of 57 health care agencies’ websites for 
published diabetes-related assessments (January 2007-May 2010). Phase II: the two 
most re-assessed drugs for which detailed information was available were selected for 
further evaluation (insulin glargine and exenatide). For these drugs, all reports pub-
lished prior to 2007 were also included. RESULTS: Phase I identiﬁ ed 117 relevant 
single technology appraisals; 18 were re-evaluations. Six agencies performed re-eval-
uations of the same drug after an initial rejection: CADTH, CVZ, HAS, PBAC, 
AHTAPol and SMC. To date, SMC evaluated 32 submissions for 13 anti-diabetic 
drugs, PBAC published 20 (eight drugs), CADTH 13 (four drugs), CVZ 14 (four 
drugs) and AHTAPol 10 (two drugs). In phase II insulin glargine (four re-submissions 
to PBAC and 1 to CADTH) and exenatide (two re-submissions to PBAC, 1 to CVZ 
and 1 to AHTAPol) were evaluated. It became clear that payers do focus on overall 
cost. The approach that was chosen for those two drugs was to control overall cost 
either by restricting access or by settling on a lower price. CVZ accepted exenatide 
for reimbursement only after restricting access to a subgroup of obese type 2 diabetes 
mellitus patients (with an ICER of c5.231). Instead of patient segmentation PBAC 
insisted on lowering the price for both medications (rationale for insulin glargine being 
concern that prescribing cannot be contained within the deﬁ ned population). 
AHTAPol limited exenatide reimbursement to 50% to control prescribing rates. 
CONCLUSIONS: For the diabetes cases analyzed HTA agencies attempted to control 
health care expenditure by either lowering drug costs or by narrowing the deﬁ nition 
of the target population, the latter inevitably allowing fewer patients access to the 
drug.
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OBJECTIVES: The AOTM in Poland was established to give MoH in Poland advice 
on reimbursement. The aim of this research is to create an overview of HTA reports 
on diabetes compounds in Poland and the results of the decision making. METHODS: 
A search was conducted on the webpage of AOTM (http://www.aotm.gov.pl) for HTA 
reports on the following products: Rosiglitazon, Pioglitazon, Sitagliptin, Vildagliptin, 
Saxagliptin, Exenatide, Liraglutide, Glargine, Detemir, Aspart, Glulisene and Lispro. 
RESULTS: Of a total of 163 reports (published between 2007 and 2010), eight reports 
in Polish language on diabetes were identiﬁ ed and assessed. Two reports can be viewed 
as secondary assessment of regulatory safety discussions. The other six reports assessed 
the implementation of new diabetes compounds with assessment of efﬁ cacy, safety 
and cost-effectiveness of the drugs.Two reports assessed safety concerns associated 
with the risk of cancer and concluded based on EMA and FDA research that no 
increased risk was associated with these agents. Rosiglitazone and Sitagliptin were not 
recommended for reimbursement due to availability of other treatments with similar 
efﬁ cacy. Saxagliptin, Exenatide and Liraglutide got the recommendation to be reim-
bursed due to expected increase in QALYs. The ﬁ nal report was assessing Glulisene 
which got the recommendation to temporary reimburse (2 years) provided that data 
on hard endpoints (not speciﬁ ed in public report) and cost-effectiveness should be 
delivered. CONCLUSIONS: Recommendation by AOTM is supported by assessment 
of available RCTs, cost per life-year gained, cost per QALY, estimated budget impact 
for 5 years and also in some cases reports from EMEA, FDA and other HTA agencies 
(SMC, PBAC and CADTH). The AOTM’s recommendation is not obligatory for the 
Polish Ministry of Health.
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OBJECTIVES: A substantial number of new pharmaceutical treatment strategies have 
been introduced for the treatment of diabetes mellitus type II. The availability of these 
drugs for patients in different countries depends on the evaluation standards and 
methods applied in the various phases of drug assessment. Objective of this research 
was to review the requirements and criteria applied for the assessment of antidiabetic 
drugs along the regulatory process by EMA (Europe) and FDA (USA) for the assess-
ment of efﬁ cacy and safety as well as for reimbursement decisions by NICE (England) 
and IQWiG (Germany) and to compare their consistency, with a special focus on 
IQWiG’s procedures. METHODS: A review of relevant current method documents 
and reports on evaluations of antidiabetic drugs published by IQWiG was conducted. 
These were compared with guidance documents issued by FDA, EMA and NICE with 
respect to endpoints considered in diabetes and their deﬁ nition, criteria for the type 
of evidence, and potential comparators. RESULTS: Consistently, across all agencies 
severe and non-severe hypoglycemias were considered highly relevant. There was, 
however, a substantial heterogeneity in the deﬁ nition of hypoglycaemias. The surro-
gate parameter HbA1C as primary endpoint was accepted by all agencies investigated 
apart from IQWiG. In its assessments, evidence from randomized as well as from 
observational studies was accepted by NICE. For safety evaluations preclinical studies 
were taken into consideration by EMA and FDA in addition to randomized controlled 
trials. IQWiG on the other hand focused exclusively on randomized controlled trials 
for the assessment of effectiveness as well as safety. CONCLUSIONS: There is a 
substantial variation of criteria applied and evidence considered relevant within the 
assessment process of IQWiG compared to other agencies. This might lead to regional 
variations in the availability of drugs. It is important to be aware of the different 
requirements of agencies, when designing trials and planning market access.
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OBJECTIVES: Disease Management Programmes (DMP) aim at improving care 
quality by implementing standards for medical practices. In the case of Diabetes Mel-
litus Type II (DM II), care improvements can be assessed by the duration between the 
ﬁ rst diagnosis and the occurrence of the ﬁ rst related complication. The aim of this 
longitudinal study is to investigate the direct inﬂ uence of the DMP-based treatments 
on patient outcomes, measured as the postponement of diabetes related complications 
in a large population of DM II patients. The study also investigates how DMP inscrip-
tions of some patients of a medical practice indirectly inﬂ uence patient outcomes of 
DM II patients, who are not inscribed in a DMP, but are treated in the same practise. 
We argue that this indirect effect is due to physicians’ learning from the DMP-based 
treatments in their clinics. METHODS: Using consultation data from IMS Health 
from a period of 25 years (1984–2009) a survival analysis is applied. The data set 
includes 161,747 DM II patients from >1100 practices. Applying a Kaplan–Meier–
Method we test for direct effects of DMPs on patient outcomes. By pooling patients 
by the registration year of the practice-leading physician and by focussing on their 
quarterly consultation rate, we test for indirect effects of DMPs on patient outcomes. 
RESULTS: The mean survival time (duration between ﬁ rst diagnosis and ﬁ rst compli-
cation) of the medical treatment of diabetics in a DMP is 14,82 years, differing sig-
niﬁ cantly from the 15,76 years without a DMP. These tests are controlled for 
following patient variables: sex, age, HbA1C, BMI and the insurance status. Learnings 
from DMPs, indirectly affecting DM care, signiﬁ cantly postpone complications for 
younger physicians and practices with fewer diabetics. CONCLUSIONS: Contributing 
to assessments of DMPs, the study discusses policy implications, as it is shown that 
care quality is improved by physicians learning from DMPs.
PDB89
PREDICTORS OF ROUTINE MONITORING OF DIABETES CARE AMONG 
THE US NON-INSTITUTIONALIZED POPULATION: A RETROSPECTIVE 
ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) IN 
2007
Zhao Y, Fonseca V, Campbell C, Shi L
Tulane University, New Orleans, LA, USA
OBJECTIVES: To examine the rate and predictors of diabetes monitoring in the US. 
METHODS: This cross-sectional retrospective study was conducted on a representa-
tive, non-institutionalized sample of the US population, using the self-reported infor-
mation from the 2007 Household Component (HC) of the MEPS. According to the 
American Diabetes Association (ADA) 2007 practice guidelines, proper provider 
monitoring is deﬁ ned as at least two A1c tests, one eye and one foot examination 
annually. Health status was measured by SF-12®Version2. a logistic regression model 
was used to examine the predictors of proper monitoring. Differences in health status 
and medical expenditures between patients with and without proper monitoring were 
examined using t-tests. Estimates were weighted to the total population (WTP). 
RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64% had at 
least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot examina-
tion. Thus, 63.36% patients (WTP: 14,065,289) received proper diabetes monitoring. 
Older patients (OR:1.021, 95% conﬁ dence interval [CI]: 1.012–1.030), non-Hispanic 
Caucasians compared with African American patients (OR: 1.236, 95% CI: 0.933–
1.636), patients with a higher education level (OR:1.211, 95% CI: 1.056–1.390), 
insurance coverage (OR:2.216, 95% CI: 1.408–3.486), use of oral anti-diabetic drugs 
(OR:2.935, 95% CI: 2.131–4.042) and insulin (OR:3.453, 95% CI: 2.477–4.814) 
were more likely to undergo the proper monitoring. Well monitored patients had a 
higher Mental Component Summary score (50.09 ± 0.37 vs. 48.51 ± 0.45, P < 0.05), 
but a lower Physical Component Summary score (39.95 ± 0.34 vs. 42.28 ± 0.47, P < 
